Dr. Charles Graham, of the Dept. of Anatomy and Cell Biology, will lead a Queen's group of investigators in the study, which has been awarded a $300,000 (US) Idea Development Award from the U.S. Army's Prostate Cancer Research Program.
The study is based on earlier findings that tumour cells exposed to very low levels of oxygen become resistant to the killing effects of anti-cancer drugs. Reduced oxygen levels contribute to the drug resistance by blocking the production of nitric oxide (NO) in the tumour cells.
"This was an exciting finding because it opened the possibility of using drugs such as nitroglycerine, which deliver NO or mimic its effects, to increase the sensitivity of cancers to conventional anti-cancer drugs," says Dr. Graham. "Most patients who die of prostate cancer do so because the tumour spreads and fails to respond to therapy."
Additional benefits of nitroglycerine – a drug that has been used to treat chest pain for more than 100 years – are that it is relatively inexpensive and that it has no significant side effects.
In assessing the grant application from the Queen's team – one of only 18 per cent that were successful – the U.S. Department of Defense review panel placed the proposal in the 98th percentile. Praising Dr. Graham's "innovative concept", the summary stated that "the review panel was highly supportive of this outstanding proposal."
The researchers will administer nitroglycerine, as well as other 'NO mimetic' drugs, to human and rodent prostate cancer cells, to test whether this is a feasible approach for increasing the sensitivity of prostate cancers to anti-cancer drugs. They also hope to develop a better understanding of how prostate cancer cells become resistant to chemotherapy.
"While this research may result in new approaches to the treatment of patients with prostate cancer, it also has the potential of leading to novel ways of enhancing the efficacy of chemotherapy against other cancers, such as breast cancer," says Dr. Graham.
Working with Dr. Graham on the Queen's prostate cancer research team is urologist Dr. Robert Siemens. Other collaborators in the research that led to this grant include Drs. Michael Adams (Pharmacology and Toxicology) and Jeremy Heaton (Urology).
Contacts:
Nancy Dorrance, Queen's News & Media Services, 613-533-2869
Lorinda Peterson, Queen's News & Media Services, 613-533-6000 ext. 77559
Attention broadcasters: Queen's now has facilities to provide broadcast quality audio and video feeds. For television interviews, we can provide a live, real-time double ender from Kingston fibre optic cable. Please call for details